LMU Medizinische Fakultät IBE IBE
Suche:
Home  |  Sitemap  |  RSS RSS  |  www.lmu.de  |  Medizinische Fakultät  |  LMU-Portal
IBE - Institut für medizinische Informationsverarbeitung, Biometrie und Epidemiologie

Fr. Dr. biol. hum., Dipl.-Math. Eva Hoster

Drittmittel
KONTAKT
Marchioninistr. 15, 81377 München
Telefon: +49 (0)89 / 440077496
E-Mail: E-Mail ehoster@ibe.med.uni-muenchen.de

Zimmer: K U1 816
Kurzlebenslauf
Seit 2002
Mitarbeiterin der Medizinischen Klinik III, Klinikum Großhadern, LMU München, unter Betreuung von Herrn Prof. Dr. J. Hasford, IBE, LMU München
Biometrikerin der German Low Grade Lymphoma Study Group (GLSG) und des European MCL Network

Bis 2002
Studium der Mathematik an der Ludwig-Maximilians-Universität München und der Friedrich-Wilhelms-Universität Bonn, Diplom 2002
Studium der Medizin an der Ludwig-Maximilians-Universität München und der Technischen Universität München, Physikum 2000, 1. Staatsexamen 2001
Arbeitsbereiche
Biometrische Betreuung Klinischer Studien (Biometrische Planung: Studiendesign, statistisches Monitoring, Fallzahlplanung; Erstellung der biometrischen Teile des Prüfplans; statistische Analyse, Berichterstellung und Publikation)
Biometrische Beratung medizinischer Doktorarbeiten und klinischer Forschungsprojekte
Prognoseforschung, Sequenzielle Studiendesigns

Arbeitsgruppen:

Studienzentrale der German Low Grade Lymphoma Study Group (GLSG) und des European MCL Network, Prof. Dr. W. Hiddemann, Medizinische Klinik III, Klinikum Großhadern, LMU München

Clinical Trials Research and Service Unit, Prof. Dr. J. Hasford, IBE, LMU München

Links:

http://www.european-mcl.net/en/clinical_mipi.php
http://med3.klinikum.uni-muenchen.de/
http://www.glsg.de/
http://www.european-mcl.net/
http://www.lymphome.de/Gruppen/GLSG/
http://www.lymphome.de/Projekte/MCL/
Lehrtätigkeit
Apothekerfortbildung bei der Landesapothekerkammer Baden-Württemberg

Dozentin für Biometrie im Studiengang Public Health der Medizinischen Fakultät der LMU München

SPSS-Kurse für Doktoranden und klinische Forscher
Publikationen
Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P, Reiser M, Forstpointner R, Metzner B, Peter N, Wörmann B, Trümper L, Pfreundschuh M, Einsele H, Hiddemann W, Unterhalt M, Dreyling M. Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma. J Clin Oncol. 2008 Dec 15. [Epub ahead of print]

Buske C, Hoster E, Dreyling M, Eimermacher H, Wandt H, Metzner B, Fuchs R, Bittenbring J, Woermann B, Hohloch K, Hess G, Ludwig WD, Schimke J, Schmitz S, Kneba M, Reiser M, Graeven U, Klapper W, Unterhalt M, Hiddemann W. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia. 2008 Sep 25. [Epub ahead of print]

Hartmann E, Fernàndez V, Moreno V, Valls J, Hernández L, Bosch F, Abrisqueta P, Klapper W, Dreyling M, Hoster E, Müller-Hermelink HK, Ott G, Rosenwald A, Campo E. Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. J Clin Oncol. 2008 Oct 20;26(30):4966-72.

Böttcher S, Ritgen M, Buske S, Gesk S, Klapper W, Hoster E, Hiddemann W, Unterhalt M, Dreyling M, Siebert R, Kneba M, Pott C; EU MCL MRD Group. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations. Haematologica. 2008 Apr;93(4):551-9.

Determann O, Hoster E, Ott G, Wolfram Bernd H, Loddenkemper C, Leo Hansmann M, Barth TE, Unterhalt M, Hiddemann W, Dreyling M, Klapper W; European Mantle Cell Lymphoma Network and the German Low Grade Lymphoma Study Group. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood. 2008 Feb 15;111(4):2385-7.

Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, Pfreundschuh M, Reiser M, Metzner B, Einsele H, Peter N, Jung W, Wörmann B, Ludwig WD, Dührsen U, Eimermacher H, Wandt H, Hasford J, Hiddemann W, Unterhalt M; German Low Grade Lymphoma Study Group (GLSG); European Mantle Cell Lymphoma Network. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008 Jan 15;111(2):558-65. Erratum in: Blood. 2008 Jun 15;111(12):5761.

Klapper W, Hoster E, Rölver L, Schrader C, Janssen D, Tiemann M, Bernd HW, Determann O, Hansmann ML, Möller P, Feller A, Stein H, Wacker HH, Dreyling M, Unterhalt M, Hiddemann W, Ott G; German Low Grade Lymphoma Study Group. Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group. J Clin Oncol. 2007 Aug 1;25(22):3330-6.

Krauss-Etschmann S, Shadid R, Campoy C, Hoster E, Demmelmair H, Jiménez M, Gil A, Rivero M, Veszprémi B, Decsi T, Koletzko BV; Nutrition and Health Lifestyle (NUHEAL) Study Group. Effects of fish-oil and folate supplementation of pregnant women on maternal and fetal plasma concentrations of docosahexaenoic acid and eicosapentaenoic acid: a European randomized multicenter trial. Am J Clin Nutr. 2007 May;85(5):1392-400.

Nickenig C, Dreyling M, Hoster E, Ludwig WD, Dörken B, Freund M, Huber C, Ganser A, Trümper L, Forstpointner R, Unterhalt M, Hiddemann W; German Low-Grade Lymphoma Study Group. Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group. Ann Oncol. 2007 Jan;18(1):136-42.

Nickenig C, Dreyling M, Hoster E, Pfreundschuh M, Trumper L, Reiser M, Wandt H, Lengfelder E, Unterhalt M, Hiddemann W; German Low-Grade Lymphoma Study Group. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Cancer. 2006 Sep 1;107(5):1014-22.

Kaml M, Weiskirchner I, Keller M, Luft T, Hoster E, Hasford J, Young L, Bartlett B, Neuner C, Fischer KH, Neuman B, Wurzner R, Grubeck-Loebenstein B. Booster vaccination in the elderly: Their success depends on the vaccine type applied earlier in life as well as on pre-vaccination antibody titers. Vaccine. 2006 Nov 17;24(47-48):6808-11.

Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood. 2006 Sep 1;108(5):1504-8.

Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, Metzner B, Truemper L, Reiser M, Steinhauer H, Boiron JM, Boogaerts MA, Aldaoud A, Silingardi V, Kluin-Nelemans HC, Hasford J, Parwaresch R, Unterhalt M, Hiddemann W. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005 Apr 1;105(7):2677-84.

Lenz G, Dreyling M, Hoster E, Wormann B, Duhrsen U, Metzner B, Eimermacher H, Neubauer A, Wandt H, Steinhauer H, Martin S, Heidemann E, Aldaoud A, Parwaresch R, Hasford J, Unterhalt M, Hiddemann W. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005 Mar 20;23(9):1984-92.

Lenz G, Dreyling M, Schiegnitz E, Haferlach T, Hasford J, Unterhalt M, Hiddemann W. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol. 2004 Dec 15;22(24):4926-33.

Lenz G, Dreyling M, Schiegnitz E, Forstpointner R, Wandt H, Freund M, Hess G, Truemper L, Diehl V, Kropff M, Kneba M, Schmitz N, Metzner B, Pfirrmann M, Unterhalt M, Hiddemann W; German Low-Grade Lymphoma Study Group. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood. 2004 Nov 1;104(9):2667-74.

Impressum - Datenschutz - Kontakt